Precipio, Inc. (PRPO) Stock Price & Analysis
Precipio, Inc. (PRPO) rose 1.39% to USD 23.32 as of June 10, 2026 at 02:00 UTC, according to Nexqual real-time market data.
PRPO last closed at USD 23; the session ranged USD 22.9–24.3 on volume of 24,495 shares. Market capitalization is $41.68M, with a 52-week range of USD 10.5–33.63 (NCM). Source: Nexqual, June 10, 2026 at 02:00 UTC.
Key Statistics (as of June 10, 2026 at 02:00 UTC)
| Price | USD 23.32 |
|---|---|
| Change | ▲ 1.39% (up) |
| Previous Close | USD 23 |
| Open | USD 23.48 |
| Day Range | USD 22.9 – 24.3 |
| 52-Week Range | USD 10.5 – 33.63 |
| Volume | 24,495 shares |
| Market Cap | $41.68M |
| Exchange | NCM |
Technical Analysis (PRPO)
Nexqual's technical model rates PRPO "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:00 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 41.58 (neutral) |
| vs SMA50 | Below (USD 26.84) |
| MACD | -1.27 (negative) |
Analyst Ratings (PRPO)
Wall Street analysts rate PRPO "None", per Nexqual as of June 10, 2026 at 02:00 UTC.
| Consensus Rating | None |
|---|
Earnings (PRPO)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2023-09-30 | USD -1.04 vs est -1.4 ▲ beat |
| 2023-06-30 | USD -1.8 vs est -2 ▲ beat |
| 2023-03-31 | USD -2.6 vs est -2.6 ▲ beat |
Source: Nexqual, June 10, 2026 at 02:00 UTC.
Financials & Fundamentals (PRPO)
| Total Revenue | $25.83M |
|---|---|
| Revenue Growth (YoY) | +36.20% |
| Gross Margin | +43.71% |
| Operating Margin | -21.28% |
| Profit Margin | -3.57% |
| ROE | -7.13% |
| Debt / Equity | 24.65 |
| Current Ratio | 1.56 |
| Total Cash | $2.60M |
| Total Debt | $3.49M |
| Free Cash Flow | $84,750 |
Source: Nexqual, June 10, 2026 at 02:00 UTC.
Financial Health Score (PRPO)
Nexqual rates Precipio, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 02:00 UTC.
| Growth | Solid — Revenue +6% YoY (annual) |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Strong — $3M cash vs $3M debt |
| Cash Flow | Mixed — FCF $85K, slim 0.9% margin |
| Efficiency | Critical — ROE -7%, ROA -5.7% |
Ownership (PRPO)
| Insider Ownership | +11.80% |
|---|---|
| Institutional Ownership | +17.60% |
| Shares Outstanding | 1.79M |
| Float | 1.43M |
| Short % of Float | +0.77% |
Source: Nexqual, June 10, 2026 at 02:00 UTC.
Leadership (PRPO)
Precipio, Inc. is led by Ilan Danieli (age 53), Founder, President, CEO & Director, per Nexqual as of June 10, 2026 at 02:00 UTC.
| Founder, President, CEO & Director | Ilan Danieli (age 53) |
|---|---|
| Chief Operating Officer | Ahmed Zaki Sabet (age 40) |
| Chief Technology Officer | Ayman A. Mohamed (age 41) |
| Chief Financial Officer | Matthew Gage (age 58) |
Major Backers & Investors (PRPO)
Notable institutional backers of Precipio, Inc. include Topline Capital Management, LLC, Renaissance Technologies, Fidelity, according to Nexqual as of June 10, 2026 at 02:00 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Topline Capital Management, LLC | 1.38% |
| Renaissance Technologies | 1.08% |
| Fidelity | 0.94% |
| Citadel | 0.85% |
| Evernest Financial Advisors, LLC | 0.53% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 3.38% |
| BlackRock | 1.62% |
| Geode Capital | 1.05% |
Source: Nexqual, June 10, 2026 at 02:00 UTC.
From Precipio, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States.
- It provides diagnostic blood cancer testing services.
- The company offers HemeScreen, a suite of robust genetic diagnostic panels; and IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages.
- It offers biomarker testing and clinical project services to bio-pharma customers.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RHEP | Regional Health Properties, Inc | USD 1.12 | ▼ 2.61% |
| CFOR | OpGen, Inc. | USD 0.5 | ▲ 0% |
| XBIO | Xenetic Biosciences, Inc. | USD 3.08 | ▼ 0.23% |
| VTVT | vTv Therapeutics Inc. | USD 31.77 | ▼ 1.15% |
| COCP | Cocrystal Pharma, Inc. | USD 1.02 | ▲ 6.25% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:00 UTC. This page is informational and not investment advice.